Mean NRS-assessed pain intensity decreased during the study, in both the ITT (5.46 ± 1.73 at V1 vs. 3.37 ± 2.43 at V4) and in the cannabis-naïve subgroup (5.92 ± 1.34 at V1 vs. 2.37 ± 1.69 at V4).
GLP-1 Drugs Offer Real Hope for People With Pain or Addiction
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic Pain ManagementAddiction MedicineGlp-1Chronic PainSubstance Use Why This MattersGLP-1 receptor agonists are showing promise beyond...